Ibrutinib plus rituximab is superior to FCR in previously untreated cll: results of the Phase III NCRI FLAIR Trial
Authors
Hillmen, P.Pitchford, A.
Bloor, Adrian
Broom, A.
Young, M.
Kennedy, B.
Walewska, R.
Furtado, M.
Preston, G.
Neilson, J. R.
Pemberton, N.
Sidra, G.
Morley, N.
Cwynarski, K.
Schuh, A.
Forconi, F.
Elmusharaf, N.
Paneesha, S.
Fox, C. P.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
Patten, P. E. M.
Allsup, D.
Munir, T.
Affiliation
St James's University Hospital, Leeds, United KingdomIssue Date
2021
Metadata
Show full item recordCitation
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398802182.Journal
BloodDOI
10.1182/blood-2021-152319Additional Links
https://dx.doi.org/10.1182/blood-2021-152319Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-152319